Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q3 2022 Earnings Conference Call November 10, 2022 10:00 AM ET Company Participants Gordon Dunn - CFO Michael Myers - CEO Conference Call Participants Aydin Huseynov - Ladenburg Thalmann James Molloy - Alliance Global Partners Naz Rahman - Maxim Group Operator Good morning and welcome to the Quoin Pharmaceuticals Limited Third Quarter Financial Results and Business Update Call. All participants will be in listen-only mode. [Operator Instructions] After today's prese ...

Table of Contents Exhibit 99.1 QUOIN PHARMACEUTICALS LTD. Condensed Consolidated Financial Statements as of September 30, 2022 and December 31, 2021 and for the three and nine months ended September 30, 2022 and 2021 (unaudited) Table of Contents QUOIN PHARMACEUTICALS LTD. Contents | | Page | | --- | --- | | Condensed Consolidated Financial Statements (Unaudited) | | | Consolidated Balance Sheets as of September 30, 2022 and December 31, 2021 | 3 | | Consolidated Statements of Operations for the three and n ...

Table of Contents Exhibit 99.1 QUOIN PHARMACEUTICALS LTD. Condensed Consolidated Financial Statements as of June 30, 2022 and December 31, 2021 and for the three and six months ended June 30, 2022 and 2021 (unaudited) 1 QUOIN PHARMACEUTICALS LTD. Quoin Pharmaceuticals Ltd. Consolidated Balance Sheets (Unaudited) | | | June 30, | | December 31, | | --- | --- | --- | --- | --- | | | | 2022 | | 2021 | | ASSETS | | | | | | Current assets: | | | | | | Cash | $ | 2,687,847 | $ | 7,482,773 | | Prepaid expenses | | ...

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q2 2022 Earnings Conference Call August 18, 2022 8:30 AM ET Company Participants Gordon Dunn - Chief Financial Officer Michael Myers - Chief Executive Officer Denise Carter - Chief Operating Officer and Director Conference Call Participants Naz Rahman - Maxim Group James Molloy - Alliance Global Partners Operator Good morning and welcome to the Quoin Pharmaceuticals Limited Second Quarter Financial Results and Business Update Call. All participants will be in listen ...

| | Page | | --- | --- | | Condensed Financial Statements (Unaudited) | | | Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021 | 3 | | Consolidated Statements of Operations for the three months ended March 31, 2022 and 2021 | 4 | | Consolidated Statements of Shareholders' Deficit as of March 31, 2022 and March 31, 2021 | 5 | | Consolidated Statements of Cash Flows for the three months ended March 31, 2022 and 2021 | 6 | | Notes to consolidated financial statements | 7 - 21 | QUOIN PHARMA ...

Table of Contents FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 OR (Mark One) ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EX ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 Commission File No.: 001-37846 CELLECT BIOTECHNOLOGY LTD. (Exact name of registrant as specified in its charter) Translation of registrant's name into English: Not applicable 23 Hata'as Street Kfar Saba, Israel 44425 (+972) (9) 974 1444 State of Israel (Jurisdiction of incorporation or organization) (A ...